ASCO: GLP-1 receptor agonists may reduce risk for obesity-related cancer, all-cause death

Published Date: 29 May 2025

For adults with diabetes and obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for obesity-related cancer compared with dipeptidyl peptidase-4 (DPP-4) inhibitors, according ...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Breast cancer prevention: How nurse practitioners and physician assistants can help

2.

FDA Expands Durvalumab Label to Operable Lung Cancer

3.

ASCO: GLP-1 receptor agonists may reduce risk for obesity-related cancer, all-cause death

4.

Mapping lifelong chronic health risks for childhood cancer survivors

5.

Adding Daratumumab to VRd Boosts MRD Negativity in Transplant-Ineligible Myeloma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot